Project Japan remains an attractive target for private equity. The industry racked up some impressive numbers in 2018, with global deals rising nearly 50%. Bain & Co. expects more of the same in 2019, as do others, but the consulting firm said “the jury is out on whether this vintage of healthcare deal returns will be as good as previous vintages.” That’s because there’s uncertainty around public stock and debt markets, among other things.
All about medicine Points: Private equity sees a lot to like in healthcare
Send us a letter
Have an opinion about this story? Click here to submit a Letter to the Editor, and we may publish it in print.
Recommended for You